DV
Dividend Vision

CRVS — Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. (CRVS)

Total return is 4.5% over the past 10.4 years, 346.3 points behind SPY at 350.8%. Its deepest 1-year drawdown was 56.4%.

CRVS is a single-stock equity holding in the healthcare sector, specifically Corvus Pharmaceuticals, Inc., a biopharmaceutical company. As a concentrated single-stock position rather than a diversified fund, it does not have a meaningful distribution rate or yield profile typical of dividend-focused ETFs. This holding appeals primarily to investors seeking targeted exposure to a specific healthcare company rather than those pursuing regular dividend income or broad sector diversification.

CRVS key facts

Asset type
Stock
Asset class
Equity
Inception date
03/23/2016
Distribution frequency
None
Last close
$14.89
Market cap
$1,252,560,896
Average volume
777900.0
Beta
0.869
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.63